Table of Contents
Nufarm’s Recovery and Strategic Shift: A Year of Transformation
A year ago, Nufarm’s shareholders faced a staggering 30% loss in a single trading session, stirring concerns about the company’s future. However, the recent surge of 13.6% in share price signals a potential turning point, with analysts acknowledging this moment as a significant earnings inflection point.
The stock’s recent rally has pushed it to its highest level since 21 May 2025, the date on which the previous interim earnings report prompted a drastic pullback in revenue targets. This resulted in a considerable $28 million inventory writedown and an alarming leverage spike to 4.5 times debt.
Performance Overview: 1H26
Nufarm’s first-half results aligned closely with market expectations, showcasing improved margins, reduced capital expenditures, and a significant drop in net leverage. Key financial figures include:
- Revenue: Down 5% year-on-year to $1.7 billion.
- Underlying Gross Profit Margin: Increased by 3.7 percentage points to 33.0%.
- Underlying EBITDA: Rose 18% to $243 million, hitting the upper range of guidance ($239-244 million).
- Underlying NPAT: Increased by 35% to $52 million.
- Net Debt: Decreased by $135 million to $1.23 billion.
- Leverage: Dropped by 20% to 3.6x, with an ambitious target of 2.0x by the end of FY26.
Additional observations include:
- Reaffirmed FY26 Guidance: Expectations for strong underlying EBITDA growth were reiterated.
- $50 Million Cost-Out Program: Progressing well, with plans for further savings of an additional $50 million by the end of FY27.
- Crop Protection Division: Continued growth was noted, driven by improved margins and effective cost management.
- Seed Technologies Update: FY26 EBITDA guidance was raised to $40 million, up from the previous $30 million, indicating positive momentum in a previously troubled segment.
The Seed Technologies division, crucially housing the Omega-3 canola initiative, had previously impacted the stock negatively. However, losses in this sector have notably decreased due to production relocation to South America and rising fish oil prices. Management is also eyeing Omega-3 deregulation in Europe and China by 2028.
Analysts’ Insights
The positive results from 1H26 have prompted a wave of upgrades and target adjustments among financial analysts. A consensus has emerged among brokers that Nufarm is on the verge of a significant earnings turnaround, with two out of three brokers raising their ratings:
- UBS: Upgraded from Neutral to Buy, increasing the target from $2.80 to $3.50, driven by sustainable crop protection margins and promising performance in emerging platforms.
- RBC Capital Markets: Upgraded from Sector Perform to Outperform, raising the target from $3.40 to $3.60, emphasising the company’s capital efficiency and progress in cost programs.
- Bell Potter: Maintained a Buy rating with a target of $3.60, noting strong revenue growth in hybrids and emerging platforms, solid cost management, and positive free cash flow.
Future Directions
As Nufarm embarks on a strategic turnaround, it faces the challenge of maintaining momentum. The company’s shares currently trade at a notable discount compared to global peers, with an EV/EBITDA ratio of 5.7x versus 9.2x for its counterparts. While analysts view this as an investment opportunity, they caution that the underlying reasons for this discount must be addressed as the company strives for consistent performance.
In summary, Nufarm’s combination of strengthened financial metrics, strategic cost management, and optimistic guidance indicates a pivotal moment for the company. Continued success in executing these strategies will be critical to narrowing the valuation gap and reinforcing investor confidence.
